Fig. 5

Effects of sorafenib on tumorigenesis-associated signaling pathways in vitro and in vivo. A Immunoblot analyses of RAF1, pERK, ERK, pAKT, AKT, c-MYC, cyclin D2, and α-tubulin in cultured HHUA-SP and -MP cells treated with or without sorafenib for 5 days. B Immunoblot analyses of RAF1, pERK, ERK, pAKT, AKT, c-MYC, cyclin D2, ZEB1, and α-tubulin in HHUA-SP- and -MP-derived tumors in mice treated orally with or without sorafenib for 4 weeks. C Each bar indicates the mean ± SEM relative density of each indicated protein obtained from three individual HHUA-SP- and -MP-derived tumor samples, as described in (B). The protein levels were normalized to that of α-tubulin. *, P < 0.01; †, P < 0.05, based on Student’s t-test